Literature DB >> 15183150

Cytokines modulate cilomilast response in lung fibroblasts.

Tadashi Kohyama1, Xiangde Liu, Fu-Qiang Wen, Tetsu Kobayashi, Qiuhong Fang, Shinji Abe, Lenora Cieslinski, Mary S Barnette, Stephen I Rennard.   

Abstract

Fibroblasts, as a major source of extracellular interstitial connective tissue matrix, play an important role in wound healing and the development of fibrosis. The phosphodiesterase (PDE) 4 inhibitor cilomilast inhibits fibroblast chemotaxis and fibroblast-mediated gel contraction. Using the Boyden blindwell chamber chemotaxis assay and the type I collagen gel contraction model, this study investigated whether specific cytokines modulate cilomilast's inhibitory effect through regulation of endogenous PGE(2) production. Human recombinant IL-1beta stimulated PGE(2) production and shifted the cilomilast concentration-dependence curve to the left in both assay systems, indicating increased sensitivity to cilomilast. In contrast, human recombinant IL-4 inhibited PGE(2) production and shifted the cilomilast concentration-dependence curve to the right in both systems. In summary, the inhibitory effect of cilomilast on fibroblast migration and collagen gel contraction is modulated by IL-1beta and IL-4 through regulation of PGE(2) production.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15183150     DOI: 10.1016/j.clim.2004.01.007

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  3 in total

1.  Synergistic effect of phosphodiesterase 4 inhibitor and serum on migration of endotoxin-stimulated macrophages.

Authors:  Jing-Xing Yang; Te-Chih Hsiung; Fu-Chun Weng; Shiau-Li Ding; Chin-Pyng Wu; Marco Conti; Tsung-Hsien Chuang; S-L Catherine Jin
Journal:  Innate Immun       Date:  2018-11       Impact factor: 2.680

2.  Interleukin-1β Modulation of the Mechanobiology of Primary Human Pulmonary Fibroblasts: Potential Implications in Lung Repair.

Authors:  Marta Gabasa; Marselina Arshakyan; Alejandro Llorente; Lourdes Chuliá-Peris; Irina Pavelescu; Antoni Xaubet; Javier Pereda; Jordi Alcaraz
Journal:  Int J Mol Sci       Date:  2020-11-10       Impact factor: 5.923

3.  BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.

Authors:  Franziska Elena Herrmann; Christian Hesslinger; Lutz Wollin; Peter Nickolaus
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.